Lab
Leconte Medical Center
Leconte Medical Center was paid $19.05M by Medicaid between Jan 2018 and Dec 2024, across 117 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoLECONTE MEDICAL CENTER
SEVIERVILLE, TN 37862
SEVIERVILLE, TN 37862
33aNPI1528052578assigned 09/06/2005
33bProvider typeClinical Medical Laboratory
28Total paid$19.05M
24GClaims363,996
24DCodes billed117
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#7 of 70
Median peer was paid$141K
This provider vs. median135×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,388 | $2.72M | |
| 2019 | 68,772 | $3.62M | |
| 2020 | 49,176 | $2.69M | |
| 2021 | 50,867 | $2.65M | |
| 2022 | 41,225 | $2.39M | |
| 2023 | 53,346 | $2.78M | |
| 2024incomplete | 40,222 | $2.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 25,004 | 23,303 | $6.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 34,479 | 32,516 | $6.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 7,869 | 7,226 | $2.98M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.3% | 10,348 | 9,810 | $1.01M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 13,856 | 12,874 | $399K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 10,512 | 9,908 | $261K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,000 | 1,456 | $183K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,976 | 34,918 | $169K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,503 | 9,081 | $126K |
| 80053 | Comprehensive metabolic panel | <1% | 31,199 | 27,079 | $109K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,334 | 7,708 | $93K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 19,504 | 17,280 | $72K |
105 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,248 | $70K |
| 87276 | <1% | 12,539 | $67K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,852 | $64K |
| 84484 | <1% | 5,094 | $61K | |
| 87275 | <1% | 12,542 | $49K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,663 | $44K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,052 | $42K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,594 | $41K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,203 | $41K |
| 83690 | <1% | 8,730 | $35K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,255 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,979 | $30K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 52 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 698 | $21K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 202 | $18K |
| 87081 | <1% | 4,902 | $17K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 794 | $14K |
| 84703 | <1% | 3,110 | $14K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 169 | $13K |
| 81001 | <1% | 12,928 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 188 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,205 | $10K |
| 94726 | <1% | 358 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,717 | $8K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 129 | $7K |
| 94729 | <1% | 915 | $6K | |
| 81003 | <1% | 5,673 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,109 | $5K |
| 87210 | <1% | 701 | $4K | |
| 83605 | <1% | 769 | $4K | |
| 77336 | <1% | 63 | $4K | |
| 85379 | <1% | 486 | $4K | |
| 87186 | <1% | 562 | $3K | |
| 81025 | <1% | 1,111 | $3K | |
| 87147 | <1% | 230 | $3K | |
| 82728 | <1% | 724 | $3K | |
| 84466 | <1% | 721 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,085 | $2K |
| 94060 | <1% | 42 | $2K | |
| 87807 | <1% | 423 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 243 | $1K |
| 83540 | <1% | 727 | $1K | |
| 83735 | <1% | 658 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 494 | $1K |
| 80061 | Lipid panel | <1% | 446 | $889.03 |
| 86850 | <1% | 56 | $810.63 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 528 | $780.49 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 28 | $748.00 |
| 86900 | <1% | 56 | $677.35 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 29 | $537.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $534.24 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 53 | $511.49 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 28 | $503.04 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 389 | $491.70 |
| 85027 | <1% | 118 | $489.44 | |
| 96417 | <1% | 26 | $482.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 16 | $411.48 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 372 | $402.32 |
| 94010 | <1% | 53 | $327.74 | |
| 86901 | <1% | 56 | $321.41 | |
| 82077 | <1% | 71 | $244.27 | |
| 87077 | <1% | 82 | $239.43 | |
| 86803 | <1% | 55 | $239.00 | |
| 86696 | <1% | 50 | $231.22 | |
| 83615 | <1% | 245 | $207.49 | |
| 86780 | <1% | 53 | $199.47 | |
| 82043 | <1% | 201 | $167.70 | |
| 86695 | <1% | 50 | $167.22 | |
| 94618 | <1% | 13 | $157.63 | |
| 87040 | <1% | 16 | $149.12 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,281 | $147.74 |
| 82947 | <1% | 18 | $141.28 | |
| 86787 | <1% | 17 | $131.11 | |
| 87340 | <1% | 41 | $129.56 | |
| 82247 | <1% | 31 | $124.43 | |
| 82607 | <1% | 46 | $119.90 | |
| 86762 | <1% | 37 | $119.07 | |
| 82550 | <1% | 16 | $92.15 | |
| 82746 | <1% | 28 | $90.81 | |
| 85730 | <1% | 14 | $85.40 | |
| 85014 | <1% | 25 | $76.80 | |
| 83880 | <1% | 30 | $70.68 | |
| 82248 | <1% | 14 | $63.88 | |
| 94727 | <1% | 12 | $61.85 | |
| 73630 | <1% | 14 | $57.45 | |
| 85610 | <1% | 14 | $56.05 | |
| 84439 | <1% | 34 | $51.53 | |
| 87581 | <1% | 16 | $45.72 | |
| 87486 | <1% | 16 | $45.72 | |
| 87541 | <1% | 16 | $45.72 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16 | $45.72 |
| 87641 | <1% | 16 | $45.72 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 48 | $43.08 |
| 73610 | <1% | 26 | $38.67 | |
| 73130 | <1% | 14 | $37.56 | |
| 82525 | <1% | 12 | $34.04 | |
| 87070 | <1% | 13 | $24.52 | |
| 87205 | <1% | 13 | $11.14 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 963 | $10.40 |
| A9270 | Non-covered item or service | 0% | 1,231 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 39 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 54 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 175 | $0.00 |
| 84702 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRINGER, RICK (VP REVENUE CYCLE)
Parent organizationCOVENANT HEALTH
| Provider | Location | Paid |
|---|---|---|
| Parkwest Medical Center | Knoxville, TN | $29.88M |
| Fort Sanders Regional Medical Center | Knoxville, TN | $26.76M |
| Morristown Hamblen Hospital Association | Morristown, TN | $17.83M |
| Methodist Medical Center | Oak Ridge, TN | $11.32M |
| Roane County Medical Center | Harriman, TN | $9.24M |
| Cumberland Medical Center, INC. | Crossville, TN | $6.06M |
| Fort Loudoun Medical Center | Lenoir City, TN | $5.86M |
| Claiborne Medical Center | Tazewell, TN | $3.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.